Table 3.
Within group comparisons of health status after TAVR: Non-iliofemoral group
| TAVR | AVR | ||||||
|---|---|---|---|---|---|---|---|
| Scale/Time Point | n | Paired Difference* (95% CI) | P value | n | Paired Difference* (95% CI) | P value | |
| KCCQ Overall Summary | |||||||
| 1 month | 34 | 3.3 (−7.3 to 13.9) | 0.529 | 25 | 5.4 (−6.2 to 17.0) | 0.348 | |
| 6 months | 39 | 19.0 (9.3 to 28.7) | <0.001 | 33 | 16.0 (7.1 to 24.9) | <0.001 | |
| 1 year | 38 | 18.7 (9.2 to 28.1) | <0.001 | 26 | 22.7 (14.5 to 30.8) | <0.001 | |
| KCCQ Physical Limitations | |||||||
| 1 month | 29 | −4.6 (−17.5 to 8.4) | 0.476 | 21 | 3.7 (−11.5 to 18.8) | 0.620 | |
| 6 months | 37 | 12.3 (0.2 to 24.4) | 0.047 | 30 | 13.6 (3.7 to 23.5) | 0.009 | |
| 1 year | 36 | 11.9 (−0.2 to 23.9) | 0.054 | 24 | 15.8 (7.1 to 24.4) | 0.001 | |
| KCCQ Total Symptoms | |||||||
| 1 month | 34 | 3.2 (−6.3 to 12.6) | 0.500 | 25 | 3.9 (−7.5 to 15.3) | 0.490 | |
| 6 months | 39 | 15.9 (8.0 to 23.8) | <0.001 | 33 | 11.2 (1.0 to 21.4) | 0.033 | |
| 1 year | 38 | 13.0 (5.1 to 21.0) | 0.002 | 26 | 19.4 (11.8 to 26.9) | <0.001 | |
| KCCQ Quality of Life | |||||||
| 1 month | 34 | 12.6 (−0.1 to 25.3) | 0.052 | 25 | 11.3 (−1.8 to 24.5) | 0.088 | |
| 6 months | 39 | 27.4 (17.4 to 37.3) | <0.001 | 31 | 23.1 (13.3 to 32.9) | <0.001 | |
| 1 year | 36 | 22.8 (11.6 to 34.0) | <0.001 | 26 | 31.1 (21.0 to 41.2) | <0.001 | |
| KCCQ Social Limitation | |||||||
| 1 month | 27 | −4.2 (−18.3 to 10.0) | 0.550 | 16 | 0.8 (−18.4 to 20.0) | 0.932 | |
| 6 months | 34 | 21.5 (7.8 to 35.3) | 0.003 | 26 | 11.1 (−4.2 to 26.5) | 0.148 | |
| 1 year | 31 | 24.8 (12.5 to 37.1) | <0.001 | 23 | 20.9 (8.0 to 33.9) | 0.003 | |
| SF-12 Physical Summary | |||||||
| 1 month | 29 | 1.7 (−2.4 to 5.8) | 0.412 | 21 | −1.0 (−5.7 to 3.7) | 0.667 | |
| 6 months | 38 | 6.3 (2.5 to 10.0) | 0.002 | 32 | 3.4 (−0.5 to 7.2) | 0.082 | |
| 1 year | 35 | 6.6 (2.4 to 10.8) | 0.003 | 25 | 6.1 (2.1 to 10.2) | 0.004 | |
| SF-12 Mental Summary | |||||||
| 1 month | 29 | −2.8 (−8.1 to 2.4) | 0.278 | 21 | 0.4 (−6.2 to 7.0) | 0.900 | |
| 6 months | 38 | 1.8 (−1.8 to 5.5) | 0.319 | 32 | 2.8 (−2.8 to 8.3) | 0.318 | |
| 1 year | 35 | 3.0 (−0.6 to 6.7) | 0.098 | 25 | 4.8 (−0.2 to 9.9) | 0.058 | |
| EQ-5D Utility | |||||||
| 1 month | 31 | −0.082 (−0.178 to 0.014) | 0.091 | 25 | −0.072 (−0.171 to 0.027) | 0.146 | |
| 6 months | 38 | 0.026 (−0.045 to 0.097) | 0.465 | 31 | 0.041 (−0.027 to 0.109) | 0.231 | |
| 1 year | 36 | 0.023 (−0.033 to 0.080) | 0.407 | 27 | 0.049 (−0.005 to 0.103) | 0.071 | |
KCCQ, Kansas City Cardiomyopathy Questionnaire; SF-12, Short Form-12
*
Paired differences reflect changes compared with baseline